Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

Target Validation and Screening Laboratory
at the Frederick National Laboratories for
Cancer Research

The Target Validation and Screening Laboratory maintains the infrastructure and expertise for the operation of cell-free and cell-based high-, medium-, and low-throughput assays. The TVSL is headed by Dr. David Evans. The TVSL is engaged in high throughput chemogenomic screening of large disease-focused panels of cell lines representing sarcoma and small cell lung cancer. The libraries to be screened are composed of compounds with largely defined mechanism(s) of action which are in routine clinical use or under active clinical investigation, providing a facile pathway for clinical translation of active compounds from the screen. Additionally, the results of this screen may define potential new targets for drug discovery against these recalcitrant, neglected cancers. The TVSL is equipped with extensive robotics, high content imaging, an Octet system for label-free quantitation of molecular (protein-protein and protein-small molecule) interactions, as well as maintaining the sarcoma and SCLC-focused cell line banks. Additionally, through the application of state-of-the-art data management techniques, TVSL is instrumental in the design and implementation of the public-facing database described above as a resource to the cancer research community.

TVSL is a central focus for initiating projects and is the hub for carrying out screening with a goal to identify potential drug targets elucidated through characterization efforts and to design screens to identify starting chemical matter to take into medicinal chemistry campaigns. A fragment library has been added to the screening sets to facilitate fragment-based drug design.

About the Branch Chief

Dr. Mary K. Wolpert, Ph.D. Dr. Beverly A. Teicher PhD is Chief of the Molecular Pharmaco-logy Branch at NCI, a position that she assumed in early 2011. One focus of the Molecular Pharmacology Branch is target and drug discovery for rare and recalcitrant cancers such as sarcoma and small cell lung cancer. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. More…